# USBC, Inc.: financial statements, quarterly

USBC · NYSE · CIK 1074828 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/usbc.md) · [Financials](/companies/usbc/financials.md) · [Filings](/companies/usbc/filings.md) · [Insiders](/companies/usbc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/usbc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q4 FY2026 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0 d](/filings/0001654954-23-015760.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [1.5 d](/filings/0001654954-24-014480.md) | [1.5](/filings/0001654954-25-001575.md) | [2.2](/filings/0001654954-25-005607.md) | [1.3](/filings/0001654954-25-009047.md) | [1.1 d](/filings/0001654954-26-002725.md) | [0.8](/filings/0001654954-26-002725.md) | [0.4](/filings/0001074828-26-000027.md) | [0.2](/filings/0001074828-26-000065.md) | [0.3 d](/filings/0001654954-26-002725.md) | [0.3](/filings/0001654954-26-002725.md) | [0.2](/filings/0001074828-26-000027.md) | [0.1](/filings/0001074828-26-000065.md) |
| Selling, general and administrative | $m | [1.1 d](/filings/0001654954-24-014480.md) | [2.0](/filings/0001654954-25-001575.md) | [2.6](/filings/0001654954-25-005607.md) | [2.5](/filings/0001654954-25-009047.md) | [2.1 d](/filings/0001654954-26-002725.md) | [2.0](/filings/0001654954-26-002725.md) | [1.8](/filings/0001074828-26-000027.md) | [1.0](/filings/0001074828-26-000065.md) | [11.5 d](/filings/0001654954-26-002725.md) | [16.9](/filings/0001654954-26-002725.md) | [11.4](/filings/0001074828-26-000027.md) | [16.4](/filings/0001074828-26-000065.md) |
| Operating income | $m | [(2.3) d](/filings/0001654954-24-014480.md) | [(3.5)](/filings/0001654954-25-001575.md) | [(4.7)](/filings/0001654954-25-005607.md) | [(3.8)](/filings/0001654954-25-009047.md) | [(3.2) d](/filings/0001654954-26-002725.md) | [(2.8)](/filings/0001654954-26-002725.md) | [(2.2)](/filings/0001074828-26-000027.md) | [(1.3)](/filings/0001074828-26-000065.md) | [(11.8) d](/filings/0001654954-26-002725.md) | [(17.1)](/filings/0001654954-26-002725.md) | [(11.7)](/filings/0001074828-26-000027.md) | [(16.4)](/filings/0001074828-26-000065.md) |
| Interest expense | $m | [0.0 d](/filings/0001654954-24-014480.md) | [0.0](/filings/0001654954-24-001790.md) | [0.7](/filings/0001654954-24-006410.md) | [0.3](/filings/0001654954-24-010633.md) | [(0.2) d](/filings/0001654954-25-014138.md) | [1.2](/filings/0001654954-25-001575.md) | [1.4](/filings/0001074828-26-000027.md) | [0.3](/filings/0001074828-26-000065.md) | [0.9 d](/filings/0001654954-25-014138.md) | not reported | [0.0](/filings/0001074828-26-000027.md) | [0.2](/filings/0001074828-26-000065.md) |
| Income tax | $m | [0.0 d](/filings/0001654954-24-014480.md) | [0.0](/filings/0001654954-25-001575.md) | [0.0](/filings/0001654954-25-005607.md) | [0.0](/filings/0001654954-25-009047.md) | [0.0 d](/filings/0001654954-26-002725.md) | [0.0](/filings/0001654954-26-002725.md) | [0.0](/filings/0001074828-26-000027.md) | [0.0](/filings/0001074828-26-000065.md) | [(0.2) d](/filings/0001654954-26-002725.md) | [(15.7)](/filings/0001654954-26-002725.md) | [(6.7)](/filings/0001074828-26-000027.md) | [(5.2)](/filings/0001074828-26-000065.md) |
| Net income | $m | [(2.9) d](/filings/0001654954-24-014480.md) | [(3.4)](/filings/0001654954-25-009047.md) | [(5.4)](/filings/0001654954-25-009047.md) | [(4.1)](/filings/0001654954-25-009047.md) | [(3.6) d](/filings/0001654954-26-002725.md) | [(4.7)](/filings/0001654954-26-002725.md) | [(3.6)](/filings/0001074828-26-000065.md) | [(1.5)](/filings/0001074828-26-000065.md) | [(12.4) d](/filings/0001654954-26-002725.md) | [(27.5)](/filings/0001654954-26-002725.md) | [(25.6)](/filings/0001074828-26-000065.md) | [(20.8)](/filings/0001074828-26-000065.md) |
| Diluted EPS | $ per share | not reported | [(0.04)](/filings/0001654954-25-001575.md) | [(2.69)](/filings/0001654954-25-005607.md) | [(2.02)](/filings/0001654954-25-009047.md) | not reported | [(0.04)](/filings/0001654954-26-002725.md) | [(1.24)](/filings/0001074828-26-000027.md) | [(0.55)](/filings/0001074828-26-000065.md) | not reported | [(0.07)](/filings/0001654954-26-002725.md) | [(0.07)](/filings/0001074828-26-000027.md) | [(0.05)](/filings/0001074828-26-000065.md) |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | [(1.24)](/filings/0001074828-26-000027.md) | [(0.55)](/filings/0001074828-26-000065.md) | not reported | not reported | [(0.07)](/filings/0001074828-26-000027.md) | [(0.05)](/filings/0001074828-26-000065.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-10-31) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | FY2026 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [4.8](/filings/0001654954-24-001790.md) | [4.7](/filings/0001654954-24-006410.md) | [2.1](/filings/0001654954-24-010633.md) | [3.1](/filings/0001654954-24-014480.md) | [1.0](/filings/0001654954-25-001575.md) | [0.4](/filings/0001654954-25-005607.md) | [0.2](/filings/0001654954-25-009047.md) | [8.8](/filings/0001654954-25-014138.md) | [4.1](/filings/0001074828-26-000065.md) | [2.0](/filings/0001074828-26-000027.md) | [3.0](/filings/0001074828-26-000065.md) |
| Current assets | $m | not reported | [4.8](/filings/0001654954-24-001790.md) | [4.7](/filings/0001654954-24-006410.md) | [2.1](/filings/0001654954-24-010633.md) | [3.1](/filings/0001654954-25-014138.md) | [1.0](/filings/0001654954-25-001575.md) | [0.4](/filings/0001654954-25-005607.md) | [0.2](/filings/0001654954-25-009047.md) | [9.8](/filings/0001654954-26-002725.md) | [6.8](/filings/0001074828-26-000065.md) | [3.4](/filings/0001074828-26-000027.md) | [4.6](/filings/0001074828-26-000065.md) |
| Total assets | $m | not reported | [5.0](/filings/0001654954-24-001790.md) | [4.9](/filings/0001654954-24-006410.md) | [2.7](/filings/0001654954-24-010633.md) | [3.7](/filings/0001654954-25-014138.md) | [1.5](/filings/0001654954-25-001575.md) | [0.9](/filings/0001654954-25-005607.md) | [0.5](/filings/0001654954-25-009047.md) | [125](/filings/0001654954-26-002725.md) | [93.7](/filings/0001074828-26-000065.md) | [72.3](/filings/0001074828-26-000027.md) | [66.5](/filings/0001074828-26-000065.md) |
| Current liabilities | $m | not reported | [3.8](/filings/0001654954-24-001790.md) | [5.1](/filings/0001654954-24-006410.md) | [6.1](/filings/0001654954-24-010633.md) | [5.2](/filings/0001654954-25-014138.md) | [5.2](/filings/0001654954-25-001575.md) | [6.6](/filings/0001654954-25-005607.md) | [5.1](/filings/0001654954-25-009047.md) | [3.7](/filings/0001654954-26-002725.md) | [3.7](/filings/0001074828-26-000065.md) | [10.7](/filings/0001074828-26-000027.md) | [20.0](/filings/0001074828-26-000065.md) |
| Total liabilities | $m | not reported | not reported | [6.7](/filings/0001654954-24-006410.md) | [7.3](/filings/0001654954-24-010633.md) | [5.8](/filings/0001654954-25-014138.md) | [5.5](/filings/0001654954-25-001575.md) | [6.8](/filings/0001654954-25-005607.md) | [5.3](/filings/0001654954-25-009047.md) | [28.0](/filings/0001654954-26-002725.md) | [12.1](/filings/0001074828-26-000065.md) | [12.4](/filings/0001074828-26-000027.md) | [20.1](/filings/0001074828-26-000065.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [3.7](/filings/0001654954-24-006410.md) | [1.2](/filings/0001654954-25-009047.md) | [(1.8)](/filings/0001654954-25-009047.md) | [(4.6)](/filings/0001654954-25-009047.md) | [(2.2)](/filings/0001654954-26-002725.md) | [(3.9)](/filings/0001074828-26-000065.md) | [(5.9)](/filings/0001074828-26-000065.md) | [(4.8)](/filings/0001074828-26-000065.md) | [97.1](/filings/0001654954-26-002725.md) | [81.5](/filings/0001074828-26-000065.md) | [59.9](/filings/0001074828-26-000065.md) | [46.4](/filings/0001074828-26-000065.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q4 FY2026 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,378) d](/filings/0001654954-24-014480.md) | [(3,393)](/filings/0001654954-25-001575.md) | [(3,655) d](/filings/0001654954-25-005607.md) | [(2,526) d](/filings/0001654954-25-009047.md) | [(3,256) d](/filings/0001654954-26-002725.md) | [(1,898)](/filings/0001654954-26-002725.md) | [(1,299)](/filings/0001074828-26-000027.md) | [(1,291) d](/filings/0001654954-25-009047.md) | [(3,107) d](/filings/0001654954-26-002725.md) | [(4,630)](/filings/0001654954-26-002725.md) | [(7,058)](/filings/0001074828-26-000027.md) | [(8,168) d](/filings/0001074828-26-000065.md) |
| Capital expenditure | $k | [(0.0) d](/filings/0001654954-24-014480.md) | [12.7](/filings/0001654954-25-001575.md) | [(0.0) d](/filings/0001654954-25-005607.md) | [53.7 d](/filings/0001654954-25-009047.md) | [0.0 d](/filings/0001654954-26-002725.md) | [0.0](/filings/0001654954-26-002725.md) | [0.0 d](/filings/0001654954-25-005607.md) | [0.0 d](/filings/0001654954-25-009047.md) | [0.0 d](/filings/0001654954-26-002725.md) | [0.0](/filings/0001654954-26-002725.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2016 (2016-06-30) | Q3 FY2017 (2017-06-30) | Q3 FY2018 (2018-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2026 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.8](/filings/0001654954-17-007570.md) | [4.0](/filings/0001654954-18-008748.md) | [8.1](/filings/0001654954-18-008748.md) | [81.1](/filings/0001654954-25-001575.md) | [2.0](/filings/0001654954-25-005607.md) | [2.1](/filings/0001654954-25-009047.md) | [108](/filings/0001654954-26-002725.md) | [2.9](/filings/0001074828-26-000027.md) | [6.7](/filings/0001074828-26-000065.md) | [388](/filings/0001654954-26-002725.md) | [388](/filings/0001074828-26-000027.md) | [388](/filings/0001074828-26-000065.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 388,144,429 at 2026-08-05, from the cover of the [10-Q filed 2026-08-07](/filings/0001074828-26-000065.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.